These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29611049)

  • 21. An Unusual Case of Synchronous Metastatic Melanomas With Differing Response to Pembrolizumab.
    Doolan BJ; McLean C; Mar V; Moore M
    J Oncol Pract; 2019 Mar; 15(3):159-160. PubMed ID: 30861362
    [No Abstract]   [Full Text] [Related]  

  • 22. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
    Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
    Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
    [No Abstract]   [Full Text] [Related]  

  • 23. [Primary central nervous system lymphoma following immunotherapy for metastatic melanoma].
    Castel M; Cotten C; Deschamps-Huvier A; Commin MH; Marguet F; Jardin F; Duval-Modeste AB; Joly P
    Ann Dermatol Venereol; 2019 Oct; 146(10):634-639. PubMed ID: 31122751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treating metastatic melanoma: Risk management].
    Lebbe C; Robert C
    Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
    [No Abstract]   [Full Text] [Related]  

  • 25. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
    Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
    Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
    [No Abstract]   [Full Text] [Related]  

  • 26. Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma.
    Kodali S; Tipirneni E; Gibson PC; Cook D; Verschraegen C; Lane KA
    Ophthalmic Plast Reconstr Surg; 2018; 34(5):e149-e151. PubMed ID: 29979269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of amputation by neoadjuvant therapy with pembrolizumab in acrolentiginous melanoma.
    Hansen I; Rünger A; Noebel C; Geidel G; Kött J; Menz A; Hildebrandt L; Schneider SW; Gebhardt C
    J Eur Acad Dermatol Venereol; 2024 Sep; 38(9):e820-e822. PubMed ID: 38421077
    [No Abstract]   [Full Text] [Related]  

  • 28. Advanced melanoma in adults: Pembrolizumab as a treatment option.
    Silvinato A; Bernardo WM; Floriano I
    Rev Assoc Med Bras (1992); 2020 May; 66(2):100-107. PubMed ID: 32428140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
    Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
    Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma.
    Schvartsman G; Perez K; Sood G; Katkhuda R; Tawbi H
    Ann Intern Med; 2017 Sep; 167(5):361-362. PubMed ID: 28761949
    [No Abstract]   [Full Text] [Related]  

  • 31. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
    Haddox CL; Shenoy N; Shah KK; Kao JC; Jain S; Halfdanarson TR; Wijdicks EF; Goetz MP
    Ann Oncol; 2017 Mar; 28(3):673-675. PubMed ID: 27993808
    [No Abstract]   [Full Text] [Related]  

  • 32. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 33. Pathological complete response after neoadjuvant pembrolizumab and radiation.
    Mynard JN; Conry RM; De Los Santos J; Gordetsky JB; Contreras CM
    Clin Exp Dermatol; 2019 Jul; 44(5):570-573. PubMed ID: 30402885
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
    Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
    J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
    Pan M; Alavi M; Herrinton LJ
    Perm J; 2018; 22():17-149. PubMed ID: 29616914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
    Yatim N; Mateus C; Charles P
    Rev Med Interne; 2018 Feb; 39(2):130-133. PubMed ID: 29277453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature.
    Shields LBE; Gordinier ME
    Gynecol Obstet Invest; 2019; 84(1):94-98. PubMed ID: 30016784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.
    Alvarez-Twose I; Martínez-Barranco P; Gotlib J; García-Montero A; Morgado JM; Jara-Acevedo M; Merker JD; Peñalver FJ; Matito A; Hou Y; Sánchez-Muñoz L; Mayado A; Mollejo M; Escribano L; Orfao A
    Leukemia; 2016 Aug; 30(8):1753-6. PubMed ID: 26876592
    [No Abstract]   [Full Text] [Related]  

  • 39. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 40. Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma.
    Cheshire SC; Board RE; Lewis AR; Gudur LD; Dobson MJ
    Radiology; 2018 Nov; 289(2):564-567. PubMed ID: 30106351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.